The drug, zoliflodacin, was highly effective in treating urogenital and rectal infections but not pharyngeal cases.
The arrival of the inevitable untreatable cases is being sped up by rising rates of gonorrhea and other STDs.
The new data mark a 4th straight year of "steep and sustained" increases.
The UK Department of Health and Social Care (DHSC) yesterday announced the launch of a £10 million ($13 million) research competition to fund innovative efforts to combat antimicrobial resistance (AMR).
Men had higher expression of antimicrobial resistance genes, a finding that may have implications for the growing threat of resistant gonorrhea.
The results show a wide diversity of gonorrhea strains both within and among nations.
The cases indicate a need for action to preserve the last remaining effective treatment.
UK officials today report good news on the outcome of the man treated for a highly resistant Neisseria gonorrhoeae infection, but they also note two similar cases in Australia.
The isolate shows high-level resistance to azithromycin and resistance to ceftriaxone.
A separate paper details ceftriaxone-resistant gonorrhea cases in Australia.